1[2]Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus (SLE).Arthritis Rheum, 1982, 25(2): 1271.
2[3]Richert KE. Hematologic complication of rheumatic disease.Hematology/Oncology. 1987,1(4):301-320.
3[4]Arnal C, Piette JC, Leone J, et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus:59 cases. J Rheumatol, 2002, 29: 75-83.
4[5]Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum, 1992,35:630-640.
5[6]Borg E J, Kallenberg CG. Treatment of severe thrombocytopenia in systemic lupus erythematosus with intravenous gammaglobulin.Ann Rheum Dis, 1992, 51: 1149-1151.
6[7]Mok CC, Lee KW, Ho CT, et al. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a Southern Chinese population. Rheumatology (Oxfoud), 2000, 39:399.
7[8]Edwaud B, Ronald H. Human megakaryocyte progenitor cells.Semin Hematol, 1998, 35: 183-191.
8[9]Richards EM, Baglin TP. Quantitation of reticulated platelets:methodology and clinical application. Br J Haematol, 1995, 91:445-451.
9[10]Watanabe K, Takeuchik TR, Kawai Y, et al. Automated measurement of reticulated platelets in estimating thrombocytopoiesis. Eur J Haematol, 1995, 54: 163-171.
10[11]Peteree SM, Brennan SA, Rinder HM, et al. Reticulated platelet values in normal and thrombocytopenic neonates. J Pediatr, 1996,129: 269-274.
